**Summary**
Oxford Biomedica plc (OXB) has issued a statement in response to recent press speculation and share price movement, confirming receipt of an unsolicited approach from EQT regarding a possible cash offer for the entire issued and to-be-issued ordinary share capital of the company. The Board of OXB is in preliminary discussions with EQT to explore whether a proposal can be made at a level that the Board would recommend. This follows earlier unsolicited proposals from EQT, which were rejected for undervaluing OXB and its prospects.
Key points
**Unsolicited Approach** EQT has expressed interest in acquiring OXB through a possible cash offer.
**Preliminary Discussions** OXB and EQT are in early talks to determine if a mutually agreeable proposal can be made.
**Previous Rejections** Earlier proposals from EQT were rejected for undervaluing the company.
**No Certainty** There is no guarantee that a firm offer will be made or what terms it might include.
**Regulatory Timeline** EQT must announce its firm intention or withdraw by February 11, 2026, unless extended by the Takeover Panel.
**Shareholder Advice** OXB shareholders are advised to take no action at this time.
**Company Background** OXB is a leading contract development and manufacturing organization (CDMO) in cell and gene therapy, with 30 years of experience in viral vectors.
The statement also includes regulatory disclosures, contact information for inquiries, and important notices regarding the involvement of financial advisers.